TOP > 外国特許検索 > PEPTIDE HAVING PROPERTY OF SPECIFICALLY ACCUMULATING IN GLIOMA, AND USE THEREOF

PEPTIDE HAVING PROPERTY OF SPECIFICALLY ACCUMULATING IN GLIOMA, AND USE THEREOF

外国特許コード F170009075
整理番号 (S2015-2036-N0)
掲載日 2017年5月29日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP081279
国際公開番号 WO 2017073485
国際出願日 平成28年10月21日(2016.10.21)
国際公開日 平成29年5月4日(2017.5.4)
優先権データ
  • 特願2015-211959 (2015.10.28) JP
発明の名称 (英語) PEPTIDE HAVING PROPERTY OF SPECIFICALLY ACCUMULATING IN GLIOMA, AND USE THEREOF
発明の概要(英語) The present invention provides a novel peptide having the property of specifically accumulating in and directly acting on a glioma. The present invention is a peptide represented by any one of the following (a) to (c): (a) a peptide formed from an amino acid sequence that includes a sequence represented by any one of SEQ ID NOs: 1, 2, and 3; (b) a peptide having the property of specifically accumulating in a glioma, and formed from an amino acid sequence that includes a sequence having undergone deletion, substitution or addition of one or more amino acids in an amino acid sequence represented by any one of SEQ ID NOs: 1, 2, and 3; and (c) a peptide having the property of specifically accumulating in a glioma, and formed from an amino acid sequence that includes a sequence at least 60% identical to a sequence represented by any one of SEQ ID NOs: 1, 2, and 3.
特許請求の範囲(英語) [claim1]
1. (A) below - (c) no peptide.
(A) Arrangement number the peptide which consists of the amino acid arrangement which includes the arrangement to which is displayed with either 1, 2 or 3,
(B) The peptide where 1 or several amino acids is deficient arrangement number at the time of amino acid arranging which is displayed with either 1, 2 or 3, consists of the amino acid arrangement which includes the arrangement which it is substituted or is added and at the same time, possesses unique accumulation characteristic in [gurioma],
(C) The peptide which arrangement number consists of the amino acid arrangement which includes the arrangement to which arrangement and the identity where is displayed with either 1, 2 or 3 are 60% or more at the same time, possesses unique accumulation characteristic in [gurioma]
[claim2]
2. In the claim 1 which is the peptide which consists of [L]-amino the peptide of statement.
[claim3]
3. In claim 1 or 2 the nuclear acid which features that the cord/code it does the peptide of statement.
[claim4]
4. The vector which features that the nuclear acid of statement is included in claim 3.
[claim5]
5. In claim the carrier which features that the peptide of statement is included 1 or 2.
[claim6]
6. Furthermore, in the claim 5 which has the sign substance or the decoration substance the carrier of statement.
[claim7]
7. The aforementioned sign substance, in the claim 6 which is the stable isotope, the radioisotope or the fluorophor the carrier of statement.
[claim8]
8. The aforementioned decoration substance, is the sugar chain or polyethylene glycol, in claim 6 or 7 the carrier of statement.
[claim9]
9. Either of the claim 5-8 the medicine composition which features the carrier of statement and that it has the bioactive substance in one section.
[claim10]
10. The for brain spinal cord tumor remedy which originates in [gurioma] or it is for diagnosis, in claim 9 the medicine composition of statement.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NIIGATA UNIVERSITY
  • 発明者(英語)
  • KONDO EISAKU
  • SAITO KEN
国際特許分類(IPC)
指定国 (WO201773485)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close